Navigation Links
Amphetamines reverse Parkinson's disease symptoms in mice

Amphetamines, including the drug popularly known as Ecstasy, can reverse the symptoms of Parkinson's disease in mice with an acute form of the condition, according to new research at Duke University Medical Center.

The researchers caution that the findings in animals do not suggest Parkinson's disease patients should find relief by taking amphetamines, which are drugs of abuse with many dangerous side effects. The findings rather indicate that drugs with similar chemical attributes might offer useful alternatives to current therapies, the researchers said.

The new study also shows that amphetamines -- normally thought to act by increasing dopamine concentrations in the brain ? correct the behavioral abnormalities associated with Parkinson's in mice devoid of the brain messenger. Dopamine normally acts on dopamine receptors ? protein switches on the surface of neurons -- to stimulate brain processes that affect movement, emotion, pleasure and mood.

Parkinson's disease stems from the degeneration of neurons in a brain region that controls movement. That degeneration, in turn, leads to a shortage of the chemical messenger dopamine. The finding that amphetamines can alter movement independently of dopamine opens up new directions in the search for prospective anti-Parkinsonian drugs, the researchers said.

The researchers, led by James B. Duke professor of cell biology Marc Caron, Ph.D. and Assistant Research Professor Raul Gainetdinov, M.D., Ph.D., of Duke, made the discovery after testing the utility of more than 60 compounds for reversing Parkinson's symptoms in a mouse model of the disease. Developed by the Duke team, the mice lack detectable brain levels of dopamine and experience essentially all the symptoms of Parkinson's disease for several hours before recovering their normal behavior. Caron is also a researcher of the Duke Institute for Genome Sciences & Policy.

The team reports its findings in the August 2005 issue of
'"/>

Source:Duke University Medical Center


Page: 1 2 3 4

Related biology news :

1. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
2. Genetic therapy reverses nervous system damage in animal model of inherited human disease
3. U of MN researchers reverse memory loss in mice
4. Targeting a key enzyme with gene therapy reversed course of Alzheimers disease in mouse models
5. Researchers develop gene therapy to reverse pulmonary arterial hypertension
6. Gene therapy reverses genetic mutation responsible for heart failure in muscular dystrophy
7. Stem cell microenvironment reverses malignant melanoma
8. Researchers reverse juvenile diabetes in animal model
9. New research demonstrates bone-marrow derived stem cells can reverse genetic kidney disease
10. Intensive statin therapy may partially reverse plaque build-up in arteries
11. Experimental drug reverses key cognitive deficits, pathology in Alzheimers
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Amphetamines reverse Parkinson disease symptoms mice

(Date:12/10/2014)... 2014 CIE San Diego has launched an ... connective tissue that enhances care coordination among social service ... client-level information; earned a second $1 million grant from ... seniors aging in community and; will be recognized as ... th 4-6p. CIE San Diego today ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
(Date:12/3/2014)... Calif. , Dec. 2, 2014   ... globally deployed, innovative test solutions for military, aerospace, ... newest version of its successful TS-900 PXI ... performance and features of high-end systems to customers ... outstanding value compared to traditional ATE. ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... Center will use IBM technologies to advance research into ... most life-threatening diseases, including cancer. The Center's research will ... biologists, Dr. Jeffrey Skolnick, the Georgia Research Alliance Eminent ... million in grants from the State of Georgia, the ...
... in the cruise industry, including cruise lines, local ... society organizations - are taking proactive measures to ... preserving cruise destinations, according to a new report ... Cruise Destinations issued by Conservation International's (CI) Center ...
... the threats that farmed Atlantic salmon escapees constitute ... are concerned about farmed salmon yet heritable changes ... genetic level are largely unknown. , In new ... have found scientific evidence that farmed salmon have ...
Cached Biology News:Georgia Tech accelerates drug discovery with new IBM supercomputing cluster 2Georgia Tech accelerates drug discovery with new IBM supercomputing cluster 3Georgia Tech accelerates drug discovery with new IBM supercomputing cluster 4Report finds cruise industry is protecting the precious places it visits 2Report finds cruise industry is protecting the precious places it visits 3Report finds cruise industry is protecting the precious places it visits 4
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 ... today that it has entered into a technology ... Company (ADM) to apply DNA2.0’s proprietary protein engineering ... engineering process. , “We are extremely excited that ... engineering platform. This proprietary bioengineering technology has ...
(Date:12/17/2014)... SAN FRANCISCO, Calif. , Dec. 17, 2014 ... results of a Phase 2 study evaluating the ... the treatment of patients with severe, chronic itch ... current standard of care, including topical steroids and ... was percent change in Visual Analog Scale (VAS) ...
(Date:12/15/2014)... NEW YORK , Dec. 15, 2014  GlassesOff ... Yuval Bar-Gil as an independent director of ... was founder of AeroScout and served as its CEO ... Decker in 2012, a $240 million transaction. Recognized as ... under Mr. Bar-Gil,s leadership, AeroScout provided Wi-Fi -based RFID ...
(Date:12/13/2014)... Maryland (PRWEB) December 12, 2014 Clarassance, ... today announced its new name: Therabron Therapeutics , ... therapy and bronchioles (a type of structure in the ... the company’s mission to develop novel protein therapeutics for ... of directors decided to change the name to mark ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... and ST. LOUIS, June 27, 2011 Verenium Corporation ... company focused on the development and commercialization of high-performance ... animal and human nutrition and health products, today announced ... suite of new enzyme products from Verenium,s late-stage product ...
... and LONDON, June 26, 2011 The pharmaceutical industry spent less ... last three years, according to data released today from the ... a Thomson Reuters business. Key highlights from the ... 21 new molecular entities (NMEs) were launched on the global market ...
... 2011 Selexis SA is a Swiss-based ... engineering of high yield and stable mammalian cell lines ... announced today it will be showcasing the new Selexis ... free SURE variant Screening at the 2011 BIO ...
Cached Biology Technology:Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes 2Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes 3Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes 4Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes 5Drug Dropout in Clinical Trials Is at Unsustainable Levels, According to Thomson Reuters, CMR International 2Drug Dropout in Clinical Trials Is at Unsustainable Levels, According to Thomson Reuters, CMR International 3Selexis SA to Give Away Euro 25,000 SUREvariant Screening Service Project at BIO 2011 2Selexis SA to Give Away Euro 25,000 SUREvariant Screening Service Project at BIO 2011 3
Rabbit polyclonal to FOXJ2 ( Abpromise for all tested applications). entrezGeneID: 55810 SwissProtID: Q9P0K8...
PI/RNase Staining Buffer Solution , 100 ml Consult technical datasheet for details....
Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
Macrophage-stimulating protein receptor...
Biology Products: